{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:57:01Z","timestamp":1788494221493,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.xphs.2025.01.028","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T23:56:18Z","timestamp":1738626978000},"page":"1605-1614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Developing ultra-high concentration formulations of human immune globulins for subcutaneous injectables"],"prefix":"10.1016","volume":"114","author":[{"given":"Jayprakash","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihab","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Civati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Liebminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Teschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt L.","family":"Trout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Braatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7468-8093","authenticated-orcid":false,"given":"Allan S.","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.xphs.2025.01.028_bib0001","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1073\/pnas.1131899100","article-title":"Crystalline monoclonal antibodies for subcutaneous delivery","volume":"100","author":"Yang","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.xphs.2025.01.028_bib0002","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J Pharm Sci"},{"issue":"13","key":"10.1016\/j.xphs.2025.01.028_bib0003","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.addr.2011.09.008","article-title":"Viscosity of concentrated therapeutic protein compositions","volume":"63","author":"Jezek","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.028_bib0004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/bit.22983","article-title":"Hydrophobic salts markedly diminish viscosity of concentrated protein solutions","volume":"108","author":"Du","year":"2011","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.xphs.2025.01.028_bib0005","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1007\/s11095-012-0802-9","article-title":"Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies","volume":"29","author":"Guo","year":"2012","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.028_bib0006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jbiosc.2013.10.016","article-title":"Arginine and lysine reduce the high viscosity of serum albumin solutions for pharmaceutical injection","volume":"117","author":"Inoue","year":"2014","journal-title":"J Biosci Bioeng"},{"issue":"6","key":"10.1016\/j.xphs.2025.01.028_bib0007","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/mp5000218","article-title":"Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations","volume":"11","author":"Inoue","year":"2014","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.028_bib0008","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.xphs.2017.01.018","article-title":"Bulky polar additives that greatly reduce the viscosity of concentrated solutions of therapeutic monoclonal antibodies","volume":"106","author":"Larson","year":"2017","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2025.01.028_bib0009","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/la9023426","article-title":"Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles","volume":"26","author":"Miller","year":"2010","journal-title":"Langmuir"},{"issue":"2","key":"10.1016\/j.xphs.2025.01.028_bib0010","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/nn204166z","article-title":"Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers","volume":"6","author":"Johnston","year":"2012","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.xphs.2025.01.028_bib0011","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/j.xphs.2019.03.008","article-title":"Enhancing stability and reducing viscosity of a monoclonal antibody with cosolutes by weakening protein-protein interactions","volume":"108","author":"Dear","year":"2019","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2025.01.028_bib0012","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.xphs.2022.12.011","article-title":"Synergistic effects of multiple excipients on controlling viscosity of concentrated protein dispersions","volume":"112","author":"Yang","year":"2023","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2025.01.028_bib0013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1517\/14712598.4.3.301","article-title":"Protein crystals for the delivery of biopharmaceuticals","volume":"4","author":"Basu","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2025.01.028_bib0014","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1529\/biophysj.106.098293","article-title":"Phase behavior of an intact monoclonal antibody","volume":"93","author":"Ahamed","year":"2007","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2025.01.028_bib0015","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s11095-013-1017-4","article-title":"Non-aqueous suspensions of antibodies are much less viscous than equally concentrated aqueous solutions","volume":"30","author":"Srinivasan","year":"2013","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2025.01.028_bib0016","unstructured":"https:\/\/www.takeda.com\/newsroom\/shire-news-releases\/2016\/frj956\/. Accessed in June 2023"},{"key":"10.1016\/j.xphs.2025.01.028_bib0017","unstructured":"https:\/\/www.gammagard.com\/primary-immunodeficiency. Accessed in June 2023"},{"issue":"22","key":"10.1016\/j.xphs.2025.01.028_bib0018","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1111\/febs.12513","article-title":"The excluded volume effect induced by poly (ethylene glycol) modulates the motility of actin filaments interacting with myosin","volume":"280","author":"Munakata","year":"2013","journal-title":"FEBS J"},{"issue":"11","key":"10.1016\/j.xphs.2025.01.028_bib0019","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1016\/j.xphs.2021.06.013","article-title":"Opalescence measurements: improvements in fundamental knowledge, identifying sources of analytical biases, and advanced applications for the development of therapeutic proteins","volume":"110","author":"Barros","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.01.028_bib0020","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1208\/s12249-011-9625-y","article-title":"Injectability evaluation: an open issue","volume":"12","author":"Cilurzo","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2025.01.028_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/5162394","article-title":"The biomechanics and optimization of the needle-syringe system for injecting triamcinolone acetonide into keloids","volume":"2016","author":"Vo","year":"2016","journal-title":"J Med Eng"},{"key":"10.1016\/j.xphs.2025.01.028_bib0022","series-title":"Finger Force Capability","first-page":"1","author":"Astin","year":"1999"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T01:40:27Z","timestamp":1741052427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0022354925000498"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.01.028","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing ultra-high concentration formulations of human immune globulins for subcutaneous injectables","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}